In the BioHarmony Drug Report Database

"Preview" Icon

Montelukast

Singulair (montelukast) is a small molecule pharmaceutical. Montelukast was first approved as Singulair on 1998-02-20. It is used to treat allergic rhinitis perennial and asthma in the USA. The pharmaceutical is active against cysteinyl leukotriene receptor 1. In addition, it is known to target uracil nucleotide/cysteinyl leukotriene receptor and cytochrome P450 2C8. Singulair’s patent is valid until 2022-10-24 (FDA).

 

Trade Name

 

Singulair
 

Common Name

 

montelukast
 

ChEMBL ID

 

CHEMBL787
 

Indication

 

allergic rhinitis perennial, asthma
 

Drug Class

 

Antiasthmatics/antiallergics: leukotriene receptor antagonists

Image (chem structure or protein)

Montelukast structure rendering